New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...

GlaxoSmithKline has received approval in Japan for its key respiratory product Seretide/Advair Diskus and its anti-thrombotic Arixtra, a move which the company says should make a significant ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...

Results of the European INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study, published in the American Journal of Respiratory and Critical Care Medicine (2008: ...

GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...

Seretide diskus, a combination inhaler and the world's biggest selling anti-asthmatic medication from the stable of GlaxoSmithkline Pharmaceutical Nigeria PLC (GSK), is set to be launched into the ...

Lagos — GLAXOSMITHKLINE Pharmaceutical Nigeria Plc (GSK), one of the leading pharmaceutical companies would today launch its anti-asthmatic drug seretide diskus, in the country. According to a ...

GlaxoSmithKline’s ageing respiratory blockbuster Advair has been living a charmed life since going off patent years ago - but as yet no-one has been able to get a generic rival approved in the key US ...

This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...